摘要
Abstract
Objective To investigate the clinical efficacy of puerarin on plasma endothelin, nitric oxide levels and myocardial ischemia of patients with coronary heart disease. Methods Sixty -eight patients with coronary heart disease were randomly divided into puerarin group (n = 34) and control group (n = 34). The control group received isosorbide mononitrate tablets and the puerarin group received puerarin in addition to the conventional therapy for the control group. After treatment, the changes of TIB, VPBs, HR, SP, ICE, plasma ET and NO in the two groups were observed. Follow-up was conducted twice a day. The frequency of angina attack and nitroglycerin consumption were recorded. Results After treatment, the frequency of angina attack and nitroglycerin consumption decreased significantly (P<0.01). The puerarin group had more significant improvement than the control group (P<0.01). After treatment, plasma ET decreased significantly (P< 0.01). Plasma NO levels increased significantly (P<0. 01). After treatment, plasma ET and NO in the puerarin group had more significant increase than those in the control group (P<0.01) . After treatment, the TIB, SP, ICE and VPBs levels in the two groups decreased significantly (P<0. 01). After treatment, the TIB and VPBs levels were significantly lower in the puerarin group than in the control group (P<0.01). Conclusion Puerarin can improve vascular endothelial cell function in patients with coronary heart disease, and effectively regulate the plasma ET and HO levels, which is an effective drug for myocardial ischemia induced by coronary heart disease.
关键词
葛根素/冠心病/心绞痛/内皮素/一氧化氮/心肌缺血Key words
puerarin/ coronary heart disease/ angina/ endothelin/ nitric oxide/ myocardial ischemia
分类
医药卫生
